Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock, $0.001 par value per share · CUSIP: 05338F306

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 550,550.00 · Class: 5.3%

  • BVF I GP LLC

    Shares: 550,550.00 · Class: 5.3%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 432,148.00 · Class: 4.2%

  • BVF II GP LLC

    Shares: 432,148.00 · Class: 4.2%

  • Biotechnology Value Trading Fund OS LP

    Shares: 40,633.00 · Class: 0.4%

  • BVF Partners OS Ltd.

    Shares: 40,633.00 · Class: 0.4%

  • BVF GP HOLDINGS LLC

    Shares: 982,698.00 · Class: 9.5%

  • BVF PARTNERS L P/IL

    Shares: 1,038,542.00 · Class: 9.99%

  • BVF INC/IL

    Shares: 1,038,542.00 · Class: 9.99%

  • LAMPERT MARK N

    Shares: 1,038,542.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-000466
Form type
SCHEDULE 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
Feb 14, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub